Phathom Pharmaceuticals, Inc. develops and commercializes treatments for gastrointestinal diseases, with news centered on VOQUEZNA® (vonoprazan), an oral potassium-competitive acid blocker. Company updates commonly cover VOQUEZNA commercialization for GERD, prescription trends, product presentations, clinical and real-world data, and vonoprazan use with antibiotics for H. pylori infection.
Recurring announcements also address financial results, expense discipline, balance-sheet actions, and guidance tied to the company's commercial execution. Phathom's pipeline-related updates include studies evaluating VOQUEZNA in eosinophilic esophagitis and publications or conference presentations involving GERD and non-erosive reflux disease.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced key presentations at three virtual investor conferences in June 2020. CEO Terrie Curran and COO Azmi Nabulsi will represent the company at:
- Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:30 PM EDT.
- Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, at 2:10 PM EDT.
- BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 4:00 PM EDT.
Executive management will also engage in one-on-one meetings. For live webcasts, visit their website.